CPI 1205 is primarily used in research settings to study the role of epigenetic regulation in various biological processes. It is known as a potent and selective inhibitor of EZH2, an enzyme involved in histone methylation, which plays a critical role in gene silencing. By inhibiting EZH2, CPI 1205 helps researchers explore its impact on cancer progression, particularly in cancers driven by aberrant EZH2 activity, such as certain lymphomas and solid tumors. This compound is valuable in preclinical studies aimed at understanding the therapeutic potential of targeting EZH2 in oncology. Additionally, it aids in the development of novel epigenetic therapies by providing insights into the mechanisms of gene expression regulation and chromatin remodeling.